Is Egrifta (Tesamorelin) Legal in Colorado?

What Is Tesamorelin and Why Does Legal Status Matter?

Tesamorelin is a 44-amino-acid synthetic analog of endogenous growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates pulsatile growth hormone secretion without the supraphysiologic GH spikes associated with exogenous GH injection. The FDA approved Egrifta under NDA 022505 on November 10, 2010, making it the only GHRH analog with full FDA-approved drug status in the United States.

That distinction matters enormously in Colorado and every other state. Tesamorelin is not a research chemical, not a "gray area" peptide, and not on the FDA's list of bulk drug substances that compounders may use without an approved drug application. It sits in a separate legal category: an approved prescription drug that may also be compounded under specific conditions.

How Egrifta Differs From Other Peptides

Peptides such as BPC-157, TB-500, and selank have never received FDA approval and remain on the agency's bulk substances "do-not-compound" list or in regulatory limbo. Tesamorelin does not share that status. The FDA's current list of bulk drug substances under consideration for 503B compounding includes tesamorelin as a candidate, acknowledging its existing approved-drug status as the baseline framework.

Why Colorado Adds No Extra Restrictions

Colorado has no state statute that specifically bans or further restricts tesamorelin beyond federal law. The Colorado Revised Statutes Title 12, Article 280 (Pharmacy Practice Act) and the Colorado Medical Practice Act (Title 12, Article 240) defer to federal scheduling and FDA status for drug classification. Because tesamorelin is neither a DEA-scheduled substance nor a state-scheduled substance under C.R.S. § 18-18-204, it requires only a valid prescription to dispense legally in Colorado.

FDA Approval: What the Clinical Evidence Actually Shows

The FDA approval rests on two key Phase 3 trials published in peer-reviewed literature, not on anecdote or small pilot data.

LIPO-010 and LIPO-011 Trials

In LIPO-010 (N=412), tesamorelin 2 mg daily for 26 weeks reduced visceral adipose tissue (VAT) by a mean of 15.2% versus a 5.0% increase in the placebo group (P<0.001), as reported in Falutz et al., NEJM 2007. The confirmatory LIPO-011 trial replicated these findings. Both trials enrolled HIV-positive adults on stable antiretroviral therapy who had excess abdominal fat consistent with lipodystrophy.

A 52-week extension analysis published in JAMA Internal Medicine (then Archives of Internal Medicine) showed that VAT reduction was maintained only in patients who continued tesamorelin; those switched to placebo regained approximately 80% of the lost visceral fat within 26 weeks. This rebound profile informs both the prescribing decision and patient counseling in Colorado clinical practice.

Metabolic and Cardiometabolic Secondary Endpoints

A secondary analysis published on PubMed (PMID 19273827) found that tesamorelin-treated patients showed statistically significant reductions in triglycerides (mean change: -50.1 mg/dL vs. Placebo, P<0.001) and improvements in waist circumference, suggesting metabolic benefits beyond fat redistribution alone. The FDA's prescribing label reflects these secondary endpoints but does not extend the approved indication to metabolic syndrome or general obesity.

How Colorado Prescribers Can Legally Prescribe Tesamorelin

A Colorado-licensed physician, physician assistant (PA), or advanced practice registered nurse (APRN) with prescriptive authority can prescribe Egrifta for any medically appropriate reason once a valid prescriber-patient relationship exists. Two distinct legal tracks apply.

Track 1: On-Label Prescription (HIV-Associated Lipodystrophy)

This is the most legally straightforward path. A Colorado provider diagnoses HIV-associated lipodystrophy per clinical criteria, documents the indication in the medical record, and writes a prescription for Egrifta 2 mg subcutaneous once daily. The prescription can be filled at any Colorado-licensed pharmacy that stocks or can order the branded product, or transmitted to a licensed out-of-state pharmacy operating legally in Colorado under Colorado Pharmacy Board Rule 3.00.50.

The prescribing information approved by FDA states: "EGRIFTA is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy." Full Prescribing Information, Theratechnologies, 2023.

Track 2: Off-Label Prescription

Off-label prescribing is legal in every U.S. State, including Colorado. The FDA's own guidance on off-label use confirms: "Once a drug is approved for one indication, physicians may prescribe it for other uses." Colorado's Medical Practice Act similarly does not prohibit off-label prescribing when supported by clinical judgment.

Common off-label uses discussed in clinical literature include age-related GH decline (somatopause), non-HIV visceral adiposity, and metabolic syndrome. A review in Endocrine Practice noted growing interest in GHRH analogs for body composition in aging, though large randomized controlled trial data outside HIV populations remain limited as of 2024.

Insurance coverage for off-label tesamorelin is nearly always denied. Patients pursuing off-label use typically pay out of pocket.

Compounding Tesamorelin in Colorado: 503A vs. 503B Rules

Compounded tesamorelin is a separate legal product from branded Egrifta. Two federal frameworks govern its legality, and Colorado pharmacies must comply with both federal and state rules.

503A: Patient-Specific Compounding Pharmacies

Under 21 U.S.C. § 503A, a state-licensed compounding pharmacy may prepare tesamorelin for an individual patient if:

1. A valid prescription exists for that specific patient.
2. The compound is not on FDA's "do-not-compound" list for 503A pharmacies.
3. The pharmacy holds an active Colorado Pharmacy Board license.

Tesamorelin is not currently on the FDA's 503A Bulks List, Negative List (the list of substances pharmacies may NOT use), meaning 503A compounding with a valid patient-specific prescription is currently permissible at the federal level. Colorado's Pharmacy Board has not added an independent state-level prohibition.

503B: Outsourcing Facilities

21 U.S.C. § 503B outsourcing facilities can produce larger batches without patient-specific prescriptions, but must register with the FDA and follow current Good Manufacturing Practice (cGMP). The FDA's 503B Bulks List currently lists tesamorelin under "Category 1" substances under evaluation, meaning it is not yet on the approved 503B bulks list nor on the prohibited list. Prescribers ordering from a 503B outsourcing facility should confirm the facility's current compliance status directly with the FDA's registered outsourcer database.

What This Means for Colorado Patients

A Colorado patient with a valid prescription from a licensed Colorado provider can legally receive compounded tesamorelin from a licensed 503A pharmacy. Receiving compounded tesamorelin from an unregistered "research chemical" vendor without a prescription is not legal under federal or Colorado law.

How to Get Egrifta (Tesamorelin) in Colorado: Step-by-Step

Getting tesamorelin legally in Colorado follows a predictable clinical pathway. The steps below apply whether you pursue branded Egrifta or compounded tesamorelin.

Step 1: Establish a Prescriber-Patient Relationship

Colorado law (C.R.S. § 12-240-107) requires a valid prescriber-patient relationship before any prescription drug is ordered. This can be established through:

• An in-person visit with a Colorado-licensed endocrinologist, internist, or functional medicine physician.
• A synchronous telemedicine visit (live video) with a Colorado-licensed provider under Colorado's telehealth parity law (H.B. 21-1198).

Audio-only visits without video may not satisfy the prescriber-patient relationship standard for new controlled or specialty prescriptions under Colorado Medical Board guidance, though tesamorelin is not scheduled.

Step 2: Complete Relevant Lab Work

A prescriber evaluating tesamorelin candidacy will typically order:

• IGF-1 (insulin-like growth factor 1) baseline to assess GH axis status. Reference ranges by age are published by the NIH.
• Fasting glucose and HbA1c. Tesamorelin may increase fasting glucose; the FDA label carries a warning for patients with or at risk for diabetes. Prescribing information confirms glucose monitoring is required.
• Lipid panel, given the drug's secondary triglyceride-lowering effect.
• For HIV indication: current CD4 count, viral load, and documentation of stable ART regimen.

Step 3: Obtain and Fill the Prescription

Once a prescription is written, Colorado patients have three options:

1. Specialty pharmacy for branded Egrifta. Theratechnologies operates a patient support program (1-877-411-EGRI) that can assist with specialty pharmacy routing and, for on-label patients, insurance prior authorization.
2. Licensed 503A compounding pharmacy. The prescriber can route the prescription to a licensed Colorado or out-of-state 503A pharmacy. Compounded tesamorelin is substantially less expensive than branded Egrifta, which has a wholesale acquisition cost exceeding $2,000 per 30-day supply.
3. 503B outsourcing facility (provider-ordered). Clinics operating under a prescriber's supervision may order from a registered 503B facility for office dispensing under Colorado's in-office dispensing rules (4 CCR 725-1, Rule 3.00.30).

Step 4: Injection Training and Follow-Up

Tesamorelin is administered as a 2 mg subcutaneous injection into the abdomen once daily. Vials require reconstitution with supplied diluent. The FDA-approved prescribing information includes full reconstitution and injection technique instructions. Follow-up IGF-1 levels at 3 months allow the prescriber to confirm physiologic response without supraphysiologic GH elevation.

Safety Profile and Contraindications Colorado Prescribers Must Document

Tesamorelin has a well-characterized safety profile from the Phase 3 trial program, but prescribers must document contraindication screening.

Absolute Contraindications

Per the FDA label, tesamorelin is contraindicated in:

• Disruption of the hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, or pituitary tumor/surgery/radiation.
• Active malignancy. GH secretagogues are contraindicated when active cancer is present due to theoretical IGF-1-mediated proliferative risk.
• Pregnancy. Tesamorelin is FDA Pregnancy Category X (now PLLR "contraindicated in pregnancy").

Common Adverse Effects

The LIPO-010 trial data, published in NEJM, identified injection site reactions (25.4% tesamorelin vs. 6.8% placebo), peripheral edema (6.6% vs. 3.9%), and arthralgia (11.6% vs. 7.8%) as the most frequent treatment-emergent adverse events. New-onset glucose intolerance occurred in a small subset, reinforcing the need for HbA1c monitoring every 3 to 6 months.

Drug Interactions

The NIH DailyMed entry for Egrifta notes that tesamorelin may alter the hepatic metabolism of drugs processed by CYP450 enzymes because GH affects CYP enzyme expression. Providers should review concurrent medications, particularly corticosteroids (which blunt GH response), and antiretrovirals that affect lipid metabolism.

Insurance Coverage in Colorado

Colorado's benchmark insurance plans follow ACA essential health benefit rules. For the on-label HIV lipodystrophy indication, coverage is possible but requires prior authorization. Cigna, Aetna, and United Healthcare plan documents available through Colorado's DORA Division of Insurance each require documentation of HIV diagnosis, current ART regimen, and measurable visceral adiposity on imaging before approving Egrifta.

Off-label use is almost universally denied. A 2022 analysis in the Journal of Managed Care and Specialty Pharmacy found that specialty peptide approvals outside narrow labeled indications had a prior authorization denial rate exceeding 70% on first submission. Patients using tesamorelin off-label in Colorado should plan for out-of-pocket costs and discuss this with their provider before initiating therapy.

Telehealth Access to Tesamorelin in Colorado

Colorado's telehealth infrastructure makes tesamorelin accessible without requiring an in-person specialist visit, provided the prescriber holds an active Colorado medical license.

Colorado H.B. 21-1198, signed into law in 2021, requires insurers to reimburse synchronous telemedicine visits at parity with in-person visits. The law does not restrict a prescriber's ability to evaluate a patient for tesamorelin via video. This means a Colorado patient anywhere in the state, including rural counties, can establish care with a licensed hormone therapy or infectious disease specialist via video, complete lab work at a local draw site, and receive a tesamorelin prescription without traveling to a metropolitan center.

HealthRX providers licensed in Colorado conduct synchronous video evaluations, review labs, and coordinate with licensed 503A compounding pharmacies for patients who qualify. The entire process from consultation to first injection may take as few as 5 to 7 business days once labs are complete.